Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/biom11040607 http://scihub22266oqcxt.onion/10.3390/biom11040607 33921886!8073203!33921886     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomolecules 2021 ; 11 (4): ä Nephropedia Template TP {{tp|p=33921886|t=2021. SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors |pdf=|usr=}}{{33921886}} gab.com Text SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors JO: Biomolecules http://www.kidney.de/pget.php?&tw=1&pmid=33921886 #FOAvip The uncontrolled spread of the COVID-19 pandemic caused by the new coronavirus SARS-CoV-2 during 2020-2021 is one of the most devastating events in the history, with remarkable impacts on the health, economic systems, and habits of the entire world population. While some effective vaccines are nowadays approved and extensively administered, the long-term efficacy and safety of this line of intervention is constantly under debate as coronaviruses rapidly mutate and several SARS-CoV-2 variants have been already identified worldwide. Then, the WHO's main recommendations to prevent severe clinical complications by COVID-19 are still essentially based on social distancing and limitation of human interactions, therefore the identification of new target-based drugs became a priority. Several strategies have been proposed to counteract such viral infection, including the repurposing of FDA already approved for the treatment of HIV, HCV, and EBOLA, inter alia. Among the evaluated compounds, inhibitors of the main protease of the coronavirus (M(pro)) are becoming more and more promising candidates. M(pro) holds a pivotal role during the onset of the infection and its function is intimately related with the beginning of viral replication. The interruption of its catalytic activity could represent a relevant strategy for the development of anti-coronavirus drugs. SARS-CoV-2 M(pro) is a peculiar cysteine protease of the coronavirus family, responsible for the replication and infectivity of the parasite. This review offers a detailed analysis of the repurposed drugs and the newly synthesized molecules developed to date for the treatment of COVID-19 which share the common feature of targeting SARS-CoV-2 M(pro), as well as a brief overview of the main enzymatic and cell-based assays to efficaciously screen such compounds. Twit Text FOAVip SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors ????Biomolecules http://www.kidney.de/pget.php?&tw=1&pmid=33921886 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33921886 #FOAvip English Wikipedia <ref>{{Cite pmid|33921886}}</ref> SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors #MMPMID33921886 Citarella A; Scala A; Piperno A; Micale N Biomolecules 2021[Apr]; 11 (4): ä PMID33921886show ga The uncontrolled spread of the COVID-19 pandemic caused by the new coronavirus SARS-CoV-2 during 2020-2021 is one of the most devastating events in the history, with remarkable impacts on the health, economic systems, and habits of the entire world population. While some effective vaccines are nowadays approved and extensively administered, the long-term efficacy and safety of this line of intervention is constantly under debate as coronaviruses rapidly mutate and several SARS-CoV-2 variants have been already identified worldwide. Then, the WHO's main recommendations to prevent severe clinical complications by COVID-19 are still essentially based on social distancing and limitation of human interactions, therefore the identification of new target-based drugs became a priority. Several strategies have been proposed to counteract such viral infection, including the repurposing of FDA already approved for the treatment of HIV, HCV, and EBOLA, inter alia. Among the evaluated compounds, inhibitors of the main protease of the coronavirus (M(pro)) are becoming more and more promising candidates. M(pro) holds a pivotal role during the onset of the infection and its function is intimately related with the beginning of viral replication. The interruption of its catalytic activity could represent a relevant strategy for the development of anti-coronavirus drugs. SARS-CoV-2 M(pro) is a peculiar cysteine protease of the coronavirus family, responsible for the replication and infectivity of the parasite. This review offers a detailed analysis of the repurposed drugs and the newly synthesized molecules developed to date for the treatment of COVID-19 which share the common feature of targeting SARS-CoV-2 M(pro), as well as a brief overview of the main enzymatic and cell-based assays to efficaciously screen such compounds. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/chemistry/*pharmacology[MESH] |COVID-19/virology[MESH] |Coronavirus 3C Proteases/*antagonists & inhibitors/chemistry/metabolism[MESH] |Drug Discovery[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |Peptidomimetics/chemistry/*pharmacology[MESH] |Protease Inhibitors/chemistry/*pharmacology[MESH] |SARS-CoV-2/chemistry/*drug effects/metabolism[MESH]SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Mo(epmc).pdf DeepDyve Pubget Overpricing